NERV
$3.21
Minerva Neuroscie
NERV
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  ($0.22)
Revenue:  $0.00 Mil
Monday
Nov 2
7:30 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when NERV reports earnings?
Beat
Meet
Miss

Where is NERV's stock price going from here?
Up
Flat
Down
Stock chart of NERV
Analysts
Summary of analysts' recommendations for NERV
Score
Grade
Pivots
Resistance
$3.44
$3.36
$3.29

$3.21

Support
$3.13
$3.05
$2.98
Tweet
Growth
Description
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The Company's pipeline will initially target the treatment of schizophrenia, major depressive disorder (MDD), insomnia, and Parkinson's disease. Its product candidates include MIN-101, MIN-117, MIN-202 and MIN-301. Minerva Neurosciences, Inc. is based in Cambridge, MA, United States.
Peers
InterCeptRegeneron PharmaceuticalsVertex PharmaceuticalsBioMarin PharmaceuticalZoetisBristol-Myers SquibbJohnson & JohnsonMerck & Co.PfizerUltragenyx Pharmaceutical